GlassScriptPhysician profile
Jeffrey C Cilley
NPI 1316028780
$7,245.10
in general payments reported to CMS, 2019-2025
47 companies · $837 in 2025
The $837 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,338 · 2020: $1,096 · 2021: $676 · 2022: $130 · 2023: $354 · 2024: $813 · 2025: $837.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,005.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,004.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $820.89 | 2019-2025 | Polivy |
| Novartis Pharmaceuticals Corporation | $781.20 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $532.06 | 2019-2023 | Keytruda, Lynparza |
| Beigene, LTD. | $525.00 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $432.41 | 2019-2025 | Opdualag, Reblozyl |
| Janssen Pharmaceuticals, INC | $369.02 | 2019-2021 | |
| Janssen Biotech, INC. | $347.70 | 2019-2021 | |
| Pfizer INC. | $334.80 | 2019-2024 | |
| Celgene Corporation | $323.33 | 2019-2025 | Reblozyl, Pomalyst |
| Astrazeneca Pharmaceuticals LP | $294.60 | 2019-2025 | Tagrisso, Imfinzi |
| Gilead Sciences, INC. | $229.78 | 2019-2025 | Trodelvy |
| Abbvie INC. | $203.46 | 2019-2025 | |
| Dendreon Pharmaceuticals LLC | $199.00 | 2019-2024 | Provenge |
| Pharmacyclics LLC, An Abbvie Company | $155.03 | 2019-2023 | Imbruvica |
| Amgen INC. | $145.27 | 2019-2020 |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Cilley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.